← Back to headlines
Pfizer-Valneva Lyme Vaccine Shows Strong Efficacy But Faces Approval Hurdles
Pfizer and Valneva reported strong efficacy data from their Lyme disease vaccine trial, though the candidate reportedly missed a specific mark, potentially complicating its path to regulatory approval from the FDA.
23 Mar, 11:51 — 23 Mar, 13:36
Source Diversity
Source Diversity
High (51/100)4 sources30/33
Spectrum spread— 3/5 buckets covered17/33
Far L
Left1
Left (1)
cnbc
Center1
Center (1)
bloomberg
Right2
Right (2)
wsjseeking-alpha
Far R
Geographic diversity— 1 region4/34
US4
ℹAll sources from US region
Sources
Showing 2 of 4 sources
cnbcMostly Factual139d ago
Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss
Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle weakness and pain.
Read full article →seeking-alphaMixed139d ago
Pfizer, Valneva SE report phase 3 results for Lyme vaccine candidate
Read full article →Coverage Timeline
First report: seeking-alpha · 23 Mar, 11:51|Full coverage: 4 · 6h|Window: 6h
